Loading...
XNASEKSO
Market cap13mUSD
Dec 24, Last price  
0.61USD
1D
0.83%
1Q
-48.74%
Jan 2017
-98.98%
IPO
-99.75%
Name

Ekso Bionics Holdings Inc

Chart & Performance

D1W1MN
XNAS:EKSO chart
P/E
P/S
0.73
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
27.71%
Rev. gr., 5y
10.03%
Revenues
18m
+41.57%
2,706,0003,302,0005,327,0008,661,00014,221,0007,353,00011,332,00013,917,0008,882,00011,246,00012,912,00018,279,000
Net income
-15m
L+4.07%
-15,042,000-12,292-33,769,000-19,590,000-23,470,000-29,122,000-26,992,000-11,694,000-16,954,000-8,432,000-14,604,000-15,198,000
CFO
-12m
L-17.93%
-11,992-15,007,000-18,269,000-24,997,000-31,226,000-22,165,000-15,772,000-8,755,000-11,156,000-14,688,000-12,054,000
Earnings
Mar 03, 2025

Profile

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
IPO date
Apr 10, 2013
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
18,279
41.57%
12,912
14.81%
11,246
26.62%
Cost of revenue
33,391
28,468
25,074
Unusual Expense (Income)
NOPBT
(15,112)
(15,556)
(13,828)
NOPBT Margin
Operating Taxes
(476)
(1,332)
Tax Rate
NOPAT
(15,112)
(15,080)
(12,496)
Net income
(15,198)
4.07%
(14,604)
73.20%
(8,432)
-50.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
661
176
37,295
BB yield
-1.91%
-1.14%
-114.71%
Debt
Debt current
1,976
2,651
229
Long-term debt
6,641
6,282
2,222
Deferred revenue
2,169
1,032
1,475
Other long-term liabilities
471
374
74
Net debt
(21)
(11,592)
(37,955)
Cash flow
Cash from operating activities
(12,054)
(14,688)
(11,156)
CAPEX
(157)
(194)
(59)
Cash from investing activities
(157)
(5,175)
(59)
Cash from financing activities
348
176
38,712
FCF
(15,344)
(21,059)
(11,477)
Balance
Cash
8,638
20,525
40,406
Long term investments
Excess cash
7,724
19,879
39,844
Stockholders' equity
(238,974)
(223,371)
(208,871)
Invested Capital
261,508
257,724
249,861
ROIC
ROCE
EV
Common stock shares outstanding
13,867
12,962
12,269
Price
2.50
110.08%
1.19
-55.09%
2.65
-56.77%
Market cap
34,668
124.75%
15,425
-52.56%
32,513
-25.96%
EV
34,646
3,833
(5,442)
EBITDA
(13,414)
(14,669)
(13,267)
EV/EBITDA
0.41
Interest
302
156
113
Interest/NOPBT